Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Palisade Bio (PALI) Operating Expenses (2016 - 2025)

Palisade Bio (PALI) has disclosed Operating Expenses for 16 consecutive years, with $2.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Operating Expenses fell 18.68% to $2.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $11.5 million, a 21.69% decrease, with the full-year FY2024 number at $14.9 million, up 11.55% from a year prior.
  • Operating Expenses was $2.9 million for Q3 2025 at Palisade Bio, up from $2.8 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $32.9 million in Q2 2021 to a low of -$22.1 million in Q4 2022.
  • A 5-year average of $3.6 million and a median of $3.6 million in 2022 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: skyrocketed 1684.79% in 2021, then crashed 89.13% in 2022.
  • Palisade Bio's Operating Expenses stood at $32.9 million in 2021, then tumbled by 167.28% to -$22.1 million in 2022, then skyrocketed by 114.27% to $3.2 million in 2023, then rose by 7.23% to $3.4 million in 2024, then fell by 13.6% to $2.9 million in 2025.
  • Per Business Quant, the three most recent readings for PALI's Operating Expenses are $2.9 million (Q3 2025), $2.8 million (Q2 2025), and $2.3 million (Q1 2025).